All Blue Capital, an investment firm, agreed to acquire Zymeworks, a clinical-stage biotechnology company, for $773m. "Alan's exceptional breadth and depth of expertise in oncology, drug development and commercialization has greatly expanded All Blue's capabilities in the biopharmaceutical industry. Alan has already made invaluable contributions during the short time he has been in consultation with the All Blue team, and I have the utmost confidence that he can deliver value to Zymeworks," Matt Novak, All Blue Capital Managing Partner.